Publications by authors named "P Husa"
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
Influenza Other Respir Viruses
August 2024
Article Synopsis
- * The overall vaccine effectiveness (VE) was found to be 49%, with higher effectiveness of 69% during the first month and declining to 40% by about 2-3 months after vaccination.
- * Notably, the vaccine showed over 70% effectiveness in protecting older adults (65 years and older) within the first month after receiving the shot.
Oxidative stress, microparticles, and E-selectin do not depend on HIV suppression.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
February 2024
Article Synopsis
- The study explored oxidative stress and inflammation in people with HIV undergoing antiretroviral treatment to see if these factors contribute to early aging diseases.
- Researchers measured oxidative stress through malondialdehyde levels and inflammation using E-selectin levels in 213 HIV-positive individuals compared to healthy controls.
- Results showed that HIV patients had significantly higher levels of oxidative stress and inflammation, independent of their viral load and immune status, suggesting these may play a role in premature aging.
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2).
View Article and Find Full Text PDFWe conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
View Article and Find Full Text PDFUnderserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey.
View Article and Find Full Text PDF